Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

January 10, 2026

Study Completion Date

February 24, 2026

Conditions
Breast Cancer
Interventions
DRUG

T, 260 mg/m2, paclitaxel for injection (albumin-bound)

T, 260 mg/m2, paclitaxel for injection (albumin-bound)

DRUG

R, 260 mg/m2, paclitaxel for injection (albumin bound).

R, 260 mg/m2, paclitaxel for injection (albumin bound).

Trial Locations (1)

471003

RECRUITING

The First Affiliated hospital of Hennan University of Science & Technology, Luoyang

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

Chongqing Traditional Chinese Medicine Hospital

OTHER

collaborator

The First Affiliated Hospital of Henan University of Science and Technology

OTHER

collaborator

Qianfoshan Hospital

OTHER

lead

Sichuan Huiyu Pharmaceutical Co., Ltd

INDUSTRY